Aurora Reports 20% YoY Uptick In Global Medical Marijuana, Expects Benefits From International Cannabis Regulatory Reforms
Aurora Reports 20% YoY Uptick In Global Medical Marijuana, Expects Benefits From International Cannabis Regulatory Reforms
大麻股在全球醫療大麻市場出現20%的年增長，預計將受益於國際大麻監管改革。
Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) announced its financial and operational results Thursday for the fourth quarter and fiscal year 2024.
奧羅拉大麻公司（納斯達克股票代碼：ACB）（多倫多證券交易所股票代碼：ACB）週四公佈了第四季度和2024財年的財務和經營業績。
The Alberta-based cannabis giant noted the year-over-year comparison quarter for the fourth quarter of 2024 ending March 31, 2024, is the third quarter of fiscal 2023 ending March 31, 2023, as the fiscal year 2023 consisted of three quarters.
這家總部位於艾伯塔省的大麻巨頭指出，截至2024年3月31日的2024年第四季度的同比比較季度是截至2023年3月31日的2023財年第三季度，因爲2023財年由三個季度組成。
The company reported a 5% year-over-year increase in revenue to CA$67.4 million ($49.1 million) in the fourth quarter.
該公司報告稱，第四季度收入同比增長5％，達到6,740萬加元（合4,910萬美元）。
Global medical cannabis net revenue grew by 20% over the same period to CA$45.6 million. The increase in net revenue1 of $7.7 million was primarily due to higher sales...
全球醫用大麻淨收入同期增長了20％，達到4560萬加...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。